Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 4/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | UBA1 | P22314 | 2/20 | 0.36 |
| ▸ | UBE2E1 | P51965 | 2/20 | 0.36 |
| ▸ | STK33 | Q9BYT3 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14897476 | 0.85 | KMO (0.47) | CHRM4KMOBRAFNTRK1PIK3C3 | |
| SCHEMBL14897771 | 0.85 | CHRM4 (0.43) | CHRM4KMOBRAFNTRK1PIK3C3 | |
| SCHEMBL14896691 | 0.85 | CSNK1D (0.39) | RBP4CASP3SENP8SENP7SENP6 | |
| SCHEMBL14897772 | 0.84 | GRM4 (0.47) | CHRM4KMOBRAFGRM4NTRK1 | |
| SCHEMBL14897696 | 0.82 | BRAF (0.51) | CHRM4KMOBRAF | |
| SCHEMBL14881675 | 0.82 | BRAF (0.41) | CHRM4KMOBRAFGRM4NTRK1 | |
| SCHEMBL14897472 | 0.82 | BRAF (0.43) | CHRM4KMOBRAFNTRK1ATR | |
| SCHEMBL14897900 | 0.82 | KMO (0.44) | CHRM4KMOBRAFGRM4NTRK1 | |
| SCHEMBL14897769 | 0.81 | TLR7 (0.43) | CHRM4KMOBRAFNTRK1PIK3C3 | |
| SCHEMBL16193111 | 0.81 | GRM4 (0.38) | RBP4CASP3SENP8SENP7SENP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2014-09-25 | — | — | US | disclosed |
| WO-2013059594-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288052-A1 | SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | RBP4 3128/4885CASP3 267/4885SENP8 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.